Finally, it is really important to make sure that the outcomes of each rule are correct – If rule passed must always be ‘Include in final result’. If rule failed will show 'Goto next rule' for each rule apart from the final rule which must be 'Exclude from final result'.
If you want to manually include patients who are staff in care homes it would be possible to manually create a List of Patients, and include this as a rule in the search.
HINT: Add another rule > Use an existing search's results
Searches CVP-A2 to CVP-A15 exclude anybody appearing in CVP-A1.
Most of these searches (A2, A3, A5, A7, A8, A9, A11, A12, A13, A14, A15) are self-explanatory as age groups.
CVP-A2 does not include frontline health and social care workers. If you want to include a manual list of these patients, it would be possible to add a List of Patients as described for the care home workers above.
CVP-A4 includes those patients who are coded as clinically extremely vulnerable – using the national "high risk" code. As with CVP-Q2, the clinically extremely vulnerable patients are only those under the age of 70, since older patients are already included in priority group 4 or higher. Patients can be added to this search during the clinical review exercise of CVP-Q2. If a clinician decides that a patient is no longer clinically extremely vulnerable, adding a code of moderate risk or low risk will remove them from the search.
CVP-A6 identifies the patients with underlying health conditions. This has been built in line with JCVI and Green Book recommendations, while the codeset generally uses the same codes used for flu at risk groups with the addition of SMI. Patients coded as clinically extremely vulnerable will not appear since they will already have been picked up in CVP-A4.
Feb 2021: v3 searches reflect a clarification by JCVI around (severe) asthma eligibility; only patients who have had an emergency admission to hospital, or those who require continuous or regular systemic steroid therapy.
CVP-A15 has been introduced in v7 in response to 12-15 year olds being invited for a first vaccination.
CVP-A16 has been introduced in v8 in response to 5-11 year olds being offered a low-dose vaccination.
B) COVID vaccinations NO PRIMARY DOSE
This folder lists everybody who hasn’t yet received a dose of COVID-19 vaccine or has declined.
You can re-run the searches in this folder periodically to find additional patients to invite or re-invite. In particular patients turning 55, 60, 65, 70, 75, and 80, may fall between the cracks due to the likely time gap between re-running each cohort to invite them. There is only a single code for a text message invitation, and nothing by phone or letter, so tracking patients who have never been invited may be a bit of a challenge in EMIS alone. If the invitation code is used, consider adding a report to CVP-B0 for an overview of when patients were last contacted.
Prior to v7 this folder was called OUTSTANDING and searches within were prefixed CVP-D.
C) COVID vaccinations FIRST PRIMARY DOSE
This folder lists everybody who has received the first dose, but not a second dose. Anybody who decided they didn’t want to receive the second vaccine should be coded with the code SARS-CoV-2 immunisation course abandoned which will remove them from CVP-C0 (the declined code will also work). Eventually anybody remaining in these searches will need follow up to complete the vaccination course.
Prior to v7 this folder was called PARTIAL COURSE.
D) COVID vaccinations SECOND PRIMARY DOSE
The searches in here find everybody who has received exactly 2 doses, broken down into the priority groups. You will be able to use the percentage of each search to track the uptake within that priority group but bear in mind any patients who have had a third dose are not counted.
Prior to v7 this folder was called COMPLETED COURSE and searches within were prefixed CVP-B.
E) COVID vaccinations THIRD DOSE
Introduced for v7, this folder shows everybody who has received 3 doses of a COVID-19 vaccine, broken down into the various priority groups. You will be able to use the percentage of each search to track the uptake within that priority group.
P) Consider immunosuppression for additional dose
This folder contains searches that help you to identify your patients who have immunosuppression and need a third or further doses of COVID vaccine for their primary course. The CMO specification states there are 4 groups that should be invited for a third primary dose of their COVID vaccination. These are listed below in figure 1
Figure 1
1. Individuals with primary or acquired immunodeficiency states at the time of vaccination due to conditions including:
- acute and chronic leukaemias, and clinically aggressive lymphomas (including Hodgkin’s lymphoma) who were under treatment or within 12 months of achieving cure
- individuals under follow up for chronic lymphoproliferative disorders including haematological malignancies such as indolent lymphoma, chronic lymphoid leukaemia, myeloma, Waldenstrom’s macroglobulinemia and other plasma cell dyscrasias (note: this list is not exhaustive)
- immunosuppression due to HIV/AIDS with a current CD4 count of <200 cells/μl for adults or children
- primary or acquired cellular and combined immune deficiencies – those with lymphopaenia (<1,000 lymphocytes/ul) or with a functional lymphocyte disorder
- those who had received an allogeneic (cells from a donor) or an autologous (using their own cells) stem cell transplant in the previous 24 months
- those who had received a stem cell transplant more than 24 months ago but had ongoing immunosuppression or graft versus host disease (GVHD)
- persistent agammaglobulinaemia (IgG < 3g/L) due to primary immunodeficiency (for example, common variable immunodeficiency) or secondary to disease/therapy
2. Individuals on immunosuppressive or immunomodulating therapy at the time of vaccination including:
- those who were receiving or had received immunosuppressive therapy for a solid organ transplant in the previous 6 months
- those who were receiving or had received in the previous 3 months targeted therapy for autoimmune disease, such as JAK inhibitors or biologic immune modulators including B-cell targeted therapies (including rituximab but in this case the recipient would be considered immunosuppressed for a 6-month period), T-cell co-stimulation modulators, monoclonal tumour necrosis factor inhibitors (TNFi), soluble TNF receptors, interleukin (IL)-6 receptor inhibitors, IL-17 inhibitors, IL 12/23 inhibitors, IL 23 inhibitors (note: this list is not exhaustive)
- those who were receiving or had received in the previous 6 months immunosuppressive chemotherapy or radiotherapy for any indication
3. Individuals with chronic immune-mediated inflammatory disease who were receiving or had received immunosuppressive therapy prior to vaccination including:
- high-dose corticosteroids (equivalent to ≥ 20mg prednisolone per day) for more than 10 days in the previous month
- long-term moderate dose corticosteroids (equivalent to ≥10mg prednisolone per day for more than 4 weeks) in the previous 3 months
- non-biological oral immune modulating drugs, such as methotrexate >20mg per week (oral and subcutaneous), azathioprine >3.0mg/kg/day, 6-mercaptopurine >1.5mg/kg/day, mycophenolate >1g/day in the previous 3 months
- certain combination therapies at individual doses lower than above, including those on ≥7.5mg prednisolone per day in combination with other immunosuppressants (other than hydroxychloroquine or sulfasalazine) and those receiving methotrexate (any dose) with leflunomide in the previous 3 months
4. Individuals who had received high-dose steroids (equivalent to >40mg prednisolone per day for more than a week) for any reason in the month before vaccination.
Individuals who had received brief immunosuppression (≤40mg prednisolone per day) for an acute episode (for example, asthma / COPD / COVID-19) and individuals on replacement corticosteroids for adrenal insufficiency are not considered severely immunosuppressed sufficient to have prevented response to the primary vaccination.
This leads to a complex situation, where if practices are to follow the letter of the guidance they will need to contact secondary care providers to identify which departments are notifying which patients and there is a potential for confusion and for some patients to slip through the net! Primary Care IT have created searches to completely mirror the CMO specification - these are CVP-P1->CVP-P13 in the P) searches folder.
The searches provided by Primary Care IT do not include an age restriction, so children under the age of 12 may be listed in the search results.
There are specific searches which will need a degree of manual checking as searches alone cannot identify the patients completely. These are:
- CVP-P3 to look at the CD4 count
- CVP-P8 to check that targeted therapy is current
- CVP-P9 to look at the date of chemo/radiotherapy to check if it was in the last 6 months
- CVP-P10 to calculate the daily dose of steroids the patient is on
- CVP-P12 to look at the combination of drugs
- CVP-P13 to calculate the daily dose of steroids the patient is on
The associated reports have been designed to help you identify quickly which patients are eligible.
If Practices are struggling with capacity and don't have the resources to review all of these patients, we have included two searches at the top of the folder; the first for patients who would usually be identified as immunocompromised for the influenza campaign (CVP-P0), the second (CVP-P0a) to identify patients who appear in the PCIT searches but NOT in CVP-P0. If Practices wish to use the flu immunocompromised patients search, we suggest reviewing these patients too to see if they are eligible. The majority are likely to be related to steroid issues.
A final word of warning – if you run the top folder it may take about 15 minutes to run all the searches.
Invite for 3rd dose (R)
Invite for SPRING booster (S)
COVID booster recall 2024 SPRING
A) Cohorts
CVP-A21) Patients living in a care home. This search looks for patients over the age of 16 recorded as living in a care home. It utilises the codes previously used by the PCN DES.
This search may be customised for each Practice to capture patients living in residential institutions not covered by the PCN DES.
Users can edit the criteria to include the number and street (or house name if more appropriate), plus the postcode.
CVP-A22) Older patients (75 or over) Identifies patients who are aged 75 or older by 30/06/2024 (for 2024 Spring booster campaign), who are not recorded as living in a care home.
CVP-A24) Over 6m who are immunosuppressed. Patients who are aged 6 months or older, who are not recorded as living in a care home, and have at least 1 immunocompromised risk factor to receive a COVID vaccination. At risk groups reflect conditions specified in Green Book Chapter 14a, Tables 3 (age 16 and over) and Table 4 (under 16).
B) Recall for COVID booster
The recall searches help practices to identify patients that require inviting for COVID vaccintation
For this campaign the codesets specified by the NHS for immunosupression do not correlate completely with the Green book. Specifically, within the codesets SPLENIC_COD and IMATRISK1_COD there are a number conditions listed which could but will not for certain mean the patient has splenic failure. Because of this PCIT have separated out patients affected by these codes so that they can be reviewed to see if you wish to recall them for vaccination or not (they may have more than one reason for being identified as needing vaccination).
Search c)i are patients who are non contentious and can be recalled for vaccination without review.
The report for "c)ii Patients to review to see if eligible" gives you a breakdown of every codeset used to make up the immunocompromised criteria so you can see for each patient which criteria they have and decide if you want to recall them for vaccination or not.
C) Vaccinated in last 3 months
This folder gives you performance figures against each of the criteria for the Spring 2024 campaign
D) Data Admin
This folder gives you other useful data admin searches to help with your campaign.
Versions
v1 - Initial 9 priority cohorts
v2 - Fix high priority code
v4 - Add data quality searches
v5 - Add searches for 12-15 cohort with underlying health conditions
v6 - Add folder P for immunosuppression
v7 - Add folder E for third dose invitation; add CVP-05 report; update all searches with wider set of COVID vaccination codes (1st - 5th dose); add searches CVP-B0 / CVP-C0 / CVP-D0 / CVP-E0 for overview of patients who fit within each folder's vaccination status logic.
v9 - updated searches for Spring booster programme 2023
v10 - updated for Autumn 2023
v10.1 - updated for Spring 2024
v10.2 - updated for Spring 2024 to separate out patients with potential hyposplenism for review
Links
https://www.gov.uk/government/news/clinically-extremely-vulnerable-receive-updated-guidance-in-line-with-new-national-restrictions
First published 18th December 2020
Updated 19th March 2024